FOLH1 and prostate cancer: In men with biochemical recurrence of prostate cancer (BCR), positron emission tomography/computed tomography (PET/CT) with radiotracers built on PSMA ligands is gaining growing use to try to localize tumor as accurately and early as possible, thereby attempting to optimize salvage therapy.